Streptococus Group B

Streptococus Group B screening detects colonisation by Group B Streptococcus (Streptococcus agalactiae) in pregnant women using a vaginal‑rectal swab analysed by culture or molecular (PCR) methods at Dubai‑certified laboratories. The test reports whether GBS is present (detected/not detected) and, when positive by culture, can include antibiotic susceptibility to guide intrapartum management. Timely detection during pregnancy supports obstetric decision‑making and reduces the risk of early‑onset GBS infection in newborns through appropriate peripartum prophylaxis.

• Group B Streptococcus (Streptococcus agalactiae) — Detected/Not detected
• GBS PCR (Nucleic Acid Amplification Test) — Positive/Negative
• Culture identification — Growth/No growth
• Antibiotic susceptibility profile (if culture-positive)

• Routine screening at 35–37 weeks of pregnancy
• Preterm labour or preterm premature rupture of membranes (PPROM)
• Maternal fever or suspected infection during labour
• History of a previous baby with GBS disease
• If GBS was previously positive earlier in the pregnancy to reassess nearer delivery

• At‑home vaginal‑rectal swab collection by trained personnel for patient comfort and convenience
• Testing performed in Dubai‑accredited laboratories with UAE‑compliant reporting
• Fast, secure result delivery via online portal or clinician reporting
• Antibiotic susceptibility results available when culture positive to guide intrapartum prophylaxis
• Clinical guidance on next steps to reduce newborn GBS risk and support obstetric planning

• At‑home vaginal‑rectal swab collection by a trained technician (no blood required)
• No fasting required; routine hygiene (avoid douching) prior to swab is advised
• Optimal timing: 35–37 weeks gestation unless earlier testing is clinically indicated
• Provide valid Emirates ID and pregnancy details for lab reporting and medical follow‑up